CTT Pharmaceuticals Uplists to OTCQB Market: Enhancing Liquidity and Visibility

CTT Pharmaceuticals Holdings, Inc. (OTCQB:CTTH) has received approval from OTC Markets Group for uplisting its common shares to the OTCQB Market, effective March 10, 2025. This strategic move is expected to enhance trading liquidity and provide a more streamlined trading experience for U.S. shareholders, as the OTCQB is a premier marketplace for early-stage pharmaceutical companies developing new technology. Companies listed on the OTCQB must maintain current reporting status and undergo annual PCAOB audits, which can lead to greater investor confidence and higher trading volumes.



The uplisting to the OTCQB Market offers several advantages for CTT Pharmaceuticals, including:

1. Increased Visibility and Accessibility: The OTCQB Market is more widely followed by investors and analysts, making it easier for them to find and research companies listed on this market. This increased exposure can lead to higher trading volumes and improved liquidity for CTT Pharmaceuticals' shares.
2. Potential for Growth: Companies listed on the OTCQB are required to maintain current reporting status and undergo annual PCAOB audits, which can instill confidence in investors and potentially lead to increased investment and growth opportunities for CTT Pharmaceuticals.
3. Strategic Advantages: By uplisting to the OTCQB, CTT Pharmaceuticals can enhance its reputation and credibility, as the OTCQB is perceived as a more prestigious market compared to the OTC Pink Sheets. This can help the company attract more investors, partners, and customers, as well as better access to capital.

However, it is essential to note that CTT Pharmaceuticals' financial health and reporting status do not currently align with the OTCQB's listing criteria. The company is not current in its reporting obligations with the SEC, has not undergone an annual PCAOB audit in recent years, and its market capitalization is significantly below the OTCQB's minimum requirement. To be listed on the OTCQB, CTT Pharmaceuticals must address these issues and meet the required standards for current reporting status, annual PCAOB audit, market capitalization, share price, and number of shareholders.

In conclusion, CTT Pharmaceuticals' uplisting to the OTCQB Market is a strategic move that can enhance the company's liquidity, visibility, and potential for growth. However, the company must address its current financial health and reporting status to meet the OTCQB's listing criteria and fully capitalize on the benefits of this uplisting. As CTT Pharmaceuticals works towards meeting these requirements, investors should monitor the company's progress and consider the potential opportunities and risks associated with this strategic development.